To date, the only two biologics that are FDA-approved and being used to treat asthma are the humanized monoclonal IgE-targeting antibody omalizumab (Xolair) and the humanized monoclonal IL-5-targeting antibody mepolizumab (Nucala; Figure 1). This evidence concerns the gene IGHE and asthma.